C

Corvus Pharmaceuticals
D

CRVS

4.71000
USD
-0.30
(-5.99%)
مفتوح الان
حجم التداول
21,303
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
302,651,652
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    0.03500
    (1.09%)
    3.23500 USD
    A
    ARWR
    0.210
    (1.08%)
    19.660 USD
    C
    CRSP
    -0.410
    (-1.01%)
    40.310 USD
    E
    EDIT
    -0.03500
    (-2.65%)
    1.28500 USD
    F
    FIXX
    0
    (0%)
    0.000000 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    REGN
    REGN
    9.69
    (1.38%)
    712.29 USD
    R
    RGNX
    -0.25000
    (-3.28%)
    7.38000 USD
    S
    SRPT
    0.080
    (0.07%)
    119.050 USD
    V
    VYGR
    -0.05000
    (-0.87%)
    5.71000 USD
    المزيد
الأخبار

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).